copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Clinical Trial Forms | FDA This page provides links to commonly used clinical trial forms relevant to clinical trials For other FDA forms, visit the FDA Forms page
21 CFR Part 54 -- Financial Disclosure by Clinical Investigators § 54 5 Agency evaluation of financial interests (a) Evaluation of disclosure statement FDA will evaluate the information disclosed under § 54 4 (a) (2) about each covered clinical study in an application to determine the impact of any disclosed financial interests on the reliability of the study
Human Gene Therapy for Retinal Disorders; Guidance for Industry . . . FDA is announcing the availability of a document entitled “Human Gene Therapy for Retinal Disorders; Guidance for Industry ” This guidance provides recommendations to stakeholders developing human GT products for retinal disorders affecting adult and pediatric patients
FORM FDA 3454 - U. S. Food and Drug Administration I understand that this certification is made in compliance with 21 CFR part 54 and that for the purposes of this statement, a clinical investigator includes the spouse and each dependent child of
Drug Approvals and Databases | FDA Web page provides quick links to everything from acronyms to wholesale distributor and third-party logistics providers reporting Additional topics include: approved REMS, drug shortages, and the
Questions and Answers on Current Good Manufacturing Practice FDA withdrew its draft guidance for industry on Powder Blends and Finished Dosage Units — Stratified In-Process Dosage Unit Sampling and Assessment What were the Agency’s major concerns with
Financial Disclosure by Clinical Investigators - OMB 0910-0396 The collection require sponsors of any drug, biologic or device marketing application to certify to the absence of clinical investigators and or disclose those financial interests as required, when covered clinical studies are submitted to FDA in support of product marketing
Product Classification - Food and Drug Administration The Ki-67 antibody is a qualitative immunohistochemical antibody intended to identify Ki-67 protein expression in human clinical tissue specimens The KI-67 antibody is indicated as an aid in
U. S. Food and Drug Administration The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the